STERIS (NYSE:STE) Issues FY 2027 Earnings Guidance

Posted by Stanley Muller on May 11th, 2026

STERIS (NYSE:STE – Get Free Report) updated its FY 2027 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 11.100-11.300 for the period, compared to the consensus estimate of 11.070. The company issued revenue guidance of $6.4 billion-$6.4 billion, compared to the consensus revenue estimate of $6.3 billion.

STERIS Stock Down 2.7%

STERIS stock traded down $5.50 during midday trading on Monday, hitting $201.95. 1,002,126 shares of the company’s stock were exchanged, compared to its average volume of 773,329. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The company has a market cap of $19.81 billion, a PE ratio of 28.17 and a beta of 0.95. The firm has a 50-day moving average of $224.30 and a two-hundred day moving average of $244.27. STERIS has a 12 month low of $195.14 and a 12 month high of $269.44.

STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 12.15% and a return on equity of 14.34%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts expect that STERIS will post 10.22 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s payout ratio is 35.15%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

Check Out Our Latest Stock Analysis on STE

Insider Activity at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $167,233.05. This trade represents a 81.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.07% of the stock is owned by insiders.

Institutional Investors Weigh In On STERIS

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. grew its holdings in shares of STERIS by 34.9% during the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 45 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in STERIS by 2.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 2,261 shares of the medical equipment provider’s stock worth $560,000 after acquiring an additional 53 shares during the last quarter. Meeder Advisory Services Inc. raised its stake in STERIS by 3.6% in the 4th quarter. Meeder Advisory Services Inc. now owns 1,534 shares of the medical equipment provider’s stock worth $389,000 after acquiring an additional 54 shares during the last quarter. Fiduciary Trust Co lifted its position in STERIS by 0.9% during the 3rd quarter. Fiduciary Trust Co now owns 6,785 shares of the medical equipment provider’s stock worth $1,679,000 after acquiring an additional 61 shares during the period. Finally, Quadrant Capital Group LLC lifted its position in STERIS by 3.2% during the 3rd quarter. Quadrant Capital Group LLC now owns 2,429 shares of the medical equipment provider’s stock worth $601,000 after acquiring an additional 75 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Company Profile

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.